CA
NZ
UK
AU
IND
US
…
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cerus Corporation develops and commercializes pathogen-reduction technology for blood transfusions, principally the INTERCEPT Blood System for platelets and plasma. Long-term growth may be driven by wider adoption in hospitals and blood centers, additional regulatory approvals and reimbursement gains, and expansion into new markets and indications, which could support revenue growth.
Key risks include regulatory and reimbursement setbacks, slow clinical adoption versus incumbent safety practices, competitive alternatives, and execution risks tied to commercialization and profitability; investors should monitor ongoing regulatory reviews and market uptake.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -15.28M | -20.76M | -37.32M | -42.34M | -54.06M |
| Minority interest | 0.01M | 0.04M | 0.10M | -0.05M | -0.00M |
| Net income | -15.63M | -20.92M | -37.49M | -42.83M | -54.38M |
| Selling general administrative | 80.91M | 75.89M | 81.41M | 83.33M | 81.29M |
| Gross profit | 112.29M | 99.52M | 86.40M | 87.09M | 67.38M |
| Reconciled depreciation | 1.43M | 1.85M | 2.60M | 2.98M | 3.15M |
| Ebit | -15.28M | -11.88M | -28.94M | -37.06M | -52.08M |
| Ebitda | -13.43M | -10.02M | -26.34M | -34.08M | -48.94M |
| Depreciation and amortization | 1.85M | 1.85M | 2.60M | 2.98M | 3.15M |
| Non operating income net other | - | - | - | -2.42M | -0.20M |
| Operating income | -8.68M | -14.22M | -30.05M | -34.08M | -48.94M |
| Other operating expenses | 214.81M | 194.50M | 186.42M | 196.13M | 179.79M |
| Interest expense | 8.34M | 8.88M | 8.39M | 5.83M | 4.92M |
| Tax provision | 0.35M | 0.20M | 0.52M | 0.49M | 0.32M |
| Net interest income | -8.34M | -8.88M | -7.85M | -5.83M | -4.92M |
| Income tax expense | 0.35M | 0.20M | 0.33M | 0.49M | 0.32M |
| Total revenue | 206.13M | 180.27M | 156.37M | 162.05M | 130.86M |
| Total operating expenses | 120.97M | 113.75M | 116.45M | 121.17M | 116.32M |
| Cost of revenue | 93.84M | 80.75M | 69.97M | 74.95M | 63.48M |
| Total other income expense net | -6.60M | -6.53M | -7.27M | -8.26M | -5.12M |
| Net income from continuing ops | -15.64M | -20.96M | -49.88M | -42.83M | -54.38M |
| Net income applicable to common shares | - | - | - | -42.78M | -54.37M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 221.86M | 200.92M | 197.75M | 218.09M | 237.50M |
| Other current assets | 5.03M | 3.64M | 3.22M | 4.56M | 5.82M |
| Total liab | 156.89M | 144.02M | 144.30M | 149.53M | 151.88M |
| Total stockholder equity | 64.22M | 56.15M | 52.65M | 67.61M | 84.62M |
| Other current liab | 25.27M | 18.94M | 19.23M | 25.20M | 25.67M |
| Common stock | 0.19M | 0.19M | 0.18M | 0.18M | 0.17M |
| Capital stock | 0.19M | 0.19M | 0.18M | 0.18M | 0.17M |
| Retained earnings | -1081.15M | -1065.53M | -1044.61M | -1007.12M | -964.34M |
| Other liab | - | - | - | 3.50M | 2.34M |
| Good will | 1.32M | 1.32M | 1.32M | 1.32M | 1.32M |
| Other assets | - | - | 0.00M | 23.15M | 23.90M |
| Cash | 19.96M | 20.27M | 11.65M | 35.59M | 48.76M |
| Total current liabilities | 100.80M | 63.61M | 67.52M | 117.06M | 78.56M |
| Current deferred revenue | 1.27M | 1.40M | 2.00M | 0.59M | 0.67M |
| Net debt | 76.98M | 77.83M | 84.35M | 51.65M | 38.83M |
| Short term debt | 46.25M | 21.57M | 22.45M | 58.26M | 16.60M |
| Short long term debt | 43.34M | 19.30M | 20.00M | 56.16M | 14.70M |
| Short long term debt total | 96.95M | 98.10M | 96.00M | 87.24M | 87.59M |
| Other stockholder equity | 1145.34M | 1121.89M | 1098.35M | 1077.34M | 1048.94M |
| Property plant equipment | - | - | - | 10.97M | 25.18M |
| Total current assets | 174.38M | 152.02M | 144.44M | 170.14M | 187.10M |
| Net tangible assets | - | - | - | 66.29M | 83.30M |
| Short term investments | 62.92M | 60.19M | 54.20M | 66.57M | 80.60M |
| Net receivables | 30.37M | 29.78M | 35.50M | 34.43M | 25.13M |
| Long term debt | 40.55M | 64.86M | 59.80M | 13.64M | 54.72M |
| Inventory | 56.10M | 38.15M | 39.87M | 29.00M | 26.79M |
| Accounts payable | 28.01M | 21.70M | 23.84M | 33.00M | 35.61M |
| Noncontrolling interest in consolidated entity | - | - | - | 0.95M | 1.00M |
| Accumulated other comprehensive income | -0.16M | -0.40M | -1.27M | -2.79M | -0.15M |
| Common stock total equity | - | - | - | 0.18M | 0.17M |
| Retained earnings total equity | - | - | - | -1007.12M | -964.34M |
| Non currrent assets other | 26.83M | 32.04M | 30.93M | 23.15M | 23.90M |
| Non current assets total | 47.48M | 48.90M | 53.31M | 47.95M | 50.40M |
| Capital lease obligations | 13.06M | 13.94M | 16.20M | 17.43M | 18.16M |
| Long term debt total | - | - | - | 13.64M | 54.72M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -2.44M | -8.13M | 7.79M | 10.46M | 13.60M |
| Change to liabilities | - | - | - | -4.91M | 12.30M |
| Total cashflows from investing activities | -8.13M | -8.13M | 8.62M | 8.46M | 12.69M |
| Net borrowings | -0.33M | 4.30M | 9.92M | 0.21M | 21.18M |
| Total cash from financing activities | 4.96M | 4.96M | 10.67M | 4.19M | 34.29M |
| Change to operating activities | - | - | - | -0.10M | 2.13M |
| Net income | -15.63M | -20.96M | -37.49M | -42.83M | -54.38M |
| Change in cash | 8.00M | 8.00M | -24.00M | -13.69M | 12.14M |
| Begin period cash flow | 13.36M | 13.36M | 37.36M | 51.04M | 38.90M |
| End period cash flow | 21.36M | 21.36M | 13.36M | 37.36M | 51.04M |
| Total cash from operating activities | 11.36M | 11.36M | -43.17M | -25.61M | -33.92M |
| Issuance of capital stock | - | - | - | - | 2.74M |
| Depreciation | 1.85M | 1.85M | 2.60M | 2.98M | 3.15M |
| Dividends paid | - | - | 10.50M | - | - |
| Change to inventory | -14.68M | 7.03M | -14.95M | -1.77M | -19.61M |
| Change to account receivables | -0.40M | 5.50M | -1.10M | -9.20M | -4.21M |
| Sale purchase of stock | - | - | -0.17M | -0.10M | 13.11M |
| Other cashflows from financing activities | 4.73M | 0.67M | 0.93M | 4.30M | 31.55M |
| Change to netincome | - | - | - | 26.52M | 26.70M |
| Capital expenditures | 2.84M | 2.84M | 4.60M | 2.00M | 0.91M |
| Change receivables | - | - | - | -9.20M | -4.21M |
| Cash flows other operating | - | - | - | 3.58M | 3.65M |
| Cash and cash equivalents changes | - | - | - | -12.96M | 13.06M |
| Change in working capital | -6.83M | 5.23M | -32.03M | -16.05M | -9.40M |
| Stock based compensation | 22.87M | 22.87M | 20.27M | 24.46M | 23.57M |
| Other non cash items | 9.09M | 2.37M | 3.49M | 5.82M | 2.67M |
| Free cash flow | 8.52M | 8.52M | -47.77M | -27.61M | -34.83M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CERS Cerus Corporation |
-0.16 6.56% |
2.28 | - | - | 2.27 | 7.40 | 2.43 | 185.16 |
| ABT Abbott Laboratories |
1.63 1.56% |
106.20 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.57 0.59% |
96.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.89 6.38% |
291.86 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. William M. Greenman | Pres, CEO & Director | 1967 |
| Dr. Laurence M. Corash | Co-Founder & Chief Scientific Officer | 1944 |
| Mr. Kevin D. Green | VP of Fin. & CFO | 1972 |
| Mr. Vivek K. Jayaraman | Chief Operating Officer | 1975 |
| Dr. Richard J. Benjamin | Chief Medical Officer | 1960 |
| Ms. Lori L. Roll | VP of Admin. & Corp. Sec. | NA |
| Mr. Matthew M. Notarianni | Sr. Director of Investor Relations | NA |
| Ms. Chrystal N. Menard | Chief Legal Officer & Gen. Counsel | 1971 |
| Lainie Corten | VP of Global Marketing | NA |
| Ms. Carol M. Moore | Sr. VP of Regulatory Affairs, Quality & Clinical | 1950 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...